跳转至内容
Merck
CN

C0430000

卡托普利

European Pharmacopoeia (EP) Reference Standard

别名:

N-[(S)-3-巯基-2-甲基丙酰基]-L-脯氨酸

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C9H15NO3S
CAS号:
分子量:
217.29
Beilstein:
477887
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

captopril

制造商/商品名称

EDQM

mp

104-108 °C (lit.)

应用

pharmaceutical (small molecule)

格式

neat

储存温度

2-8°C

SMILES字符串

C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O

InChI

1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1

InChI key

FAKRSMQSSFJEIM-RQJHMYQMSA-N

基因信息

human ... ACE(1636)

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Captopril EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

血管紧张素转换酶抑制剂。抑制血管紧张素 II 的形成,血管紧张素 II 是生物活性多肽,可促进血管生成并增加微血管密度。

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Health hazard

警示用语:

Danger

危险声明

预防措施声明

危险分类

Muta. 2 - Repr. 1B

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable


Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Antonio C M Camargo et al.
Toxicon : official journal of the International Society on Toxinology, 59(4), 516-523 (2011-08-13)
The identification of novel endogenous and exogenous molecules acting in the complex mechanism of regulating the vascular tonus has always been of great interest. The discovery of bradykinin (1949) and the bradykinin-potentiating peptides (1965) had a pivotal influence in the
R I Ogilvie et al.
The Canadian journal of cardiology, 14(8), 1025-1033 (1998-09-17)
Twenty-four splenectomized dogs were subjected to rapid right ventricular pacing (RRVP) at 250 beats/min for five weeks. During the final three weeks, four groups six dogs were untreated or treated with captopril alone, with the angiotensin II type 1 (AT1)
Johannes J Kovarik et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 30(1), 115-123 (2014-08-12)
Blockade of the renin-angiotensin system (RAS) exerts beneficial effects in patients with mild-to-moderate chronic kidney disease, yet evidence suggesting a similar benefit in haemodialysis (HD) patients is not available. Furthermore, knowledge of the effects of RAS blockade on systemic RAS
Samir Attoub et al.
Annals of the New York Academy of Sciences, 1138, 65-72 (2008-10-08)
Lung cancer is the most common form of cancer in the world, and 90% of patients die from their disease. The angiotensin converting enzyme (ACE) inhibitors are used widely as antihypertensive agents, and it has been suggested that they decrease
Javed Mahmood et al.
International journal of radiation oncology, biology, physics, 89(4), 722-728 (2014-05-29)
To investigate the outcome of suppression of the renin angiotensin system using captopril combined with an antioxidant (Eukarion [EUK]-207) for mitigation of radiation-induced lung damage in rats. The thoracic cavity of female Sprague-Dawley rats was irradiated with a single dose

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门